MNMD

Mind Medicine (MindMed) Inc.

3.23 USD

Last updated Dec 10, 20:21 UTC

Yesterday HIGH

$3.31

Yesterday LOW

$3.13

52w HIGH

$5.01

52w LOW

$2.12

EPS

-0.45

PE

-7.18

Next Earnings

Mar 7, 2024

Overview News Government Trades

Mind Medicine (MindMed) Inc. stock is up 29.2% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 December’s closed higher than November.

Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

mindmed.co

Lara Goldstein

Tue Sep 26, 2023

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Lara Goldstein

Mon Sep 18, 2023

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Lara Goldstein

Mon Sep 18, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly 19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).
Lara Goldstein

Wed Sep 13, 2023

Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips, New Study Shows

Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined with either psilocybin or LSD.
Lara Goldstein

Tue Sep 12, 2023

Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years, NY Consulting Firm Predicts

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
The Dales Report

Tue Sep 12, 2023

MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone

MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders,
Bill Haddad

Tue Sep 12, 2023

MindMed Completes Enrollment Of Phase 2b Trial Of MM-120 In Generalized Anxiety Disorder (GAD)
Lara Goldstein

Mon Sep 11, 2023

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Lara Goldstein

Tue Sep 5, 2023

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Happy Mohamed

Thu Aug 31, 2023

'One Dose Of Psilocybin May Have Lasting Effects On Major Depression, Study Finds' - StatNews

https://www.statnews.com/2023/08/31/psilocybin-major-depression-lasting-effects/ A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized